美国食品和药物管理局(FDA)已批准强生公司治疗银屑病的口服药物，用于体重不低于40公斤的12岁及以上成人和儿童中度至重度斑块状银屑病患者。该药将帮助强生拓展银屑病市场，因为其畅销注射剂Stelara正面临着来自低价山寨药的日益激烈的竞争。该口服药物的品牌名为Icotyde，将与百时美施贵宝的Sotyktu和艾伯维的Skyrizi竞争。
美国食品和药物管理局(FDA)已批准强生公司治疗银屑病的口服药物，用于体重不低于40公斤的12岁及以上成人和儿童中度至重度斑块状银屑病患者。该药将帮助强生拓展银屑病市场，因为其畅销注射剂Stelara正面临着来自低价山寨药的日益激烈的竞争。该口服药物的品牌名为Icotyde，将与百时美施贵宝的Sotyktu和艾伯维的Skyrizi竞争。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.